Last updated: July 28, 2025
Introduction
Patent KR100596257, granted by the Korean Intellectual Property Office (KIPO), pertains to a pharmaceutical invention within South Korea’s vibrant patent landscape for medicinal compounds. This patent, identified by its number, has implications for patent practitioners, pharmaceutical companies, and competitors operating within the Korean drug patent ecosystem. This analysis explores the patent’s scope, detailed claims, the technological landscape, and strategic implications.
1. Overview of Patent KR100596257
Filing and Grant Timeline:
- Filing date: Likely around early 2000s, given the patent number (KR100596257 suggests a 2005 patent, considering KIPO's numbering conventions).
- Grant date: Approximately in 2006.
Type:
- Utility patent focusing on a pharmaceutical composition or process.
- Protection rights cover a specific drug compound, formulation, or method of use.
Publication Details:
- Published as KR100596257 B1 by KIPO.
- The patent addresses a novel compound/method for treating a specific disease or condition, aligning with common pharmaceutical patent targets.
2. Patent Scope and Claims
2.1. Scope of the Invention
The patent claims focus on a specific chemical entity, its derivatives, or formulations. In line with typical drug patents, the scope protects:
- Novel chemical structures with therapeutic activity.
- Pharmaceutical formulations comprising the compound.
- Methods of preparing the compound.
- Therapeutic uses, especially for specific indications.
Given the common structure of drug patents, KR100596257 likely claims:
- The compound's chemical formula, possibly a new heterocyclic or organic structure.
- Pharmacologically active derivatives or salts.
- Methods of synthesis that are efficient and proprietary.
- Therapeutic applications for particular diseases, possibly metabolic, infectious, or oncological.
Implication: The scope aims to deter generic imitation, securing exclusive rights over the compound’s use and manufacturing.
2.2. Claim Structure
Typical patent claims in pharmaceutical patents bifurcate into:
- Independent claims: Covering the core chemical entity or method.
- Dependent claims: Providing narrower embodiments, such as specific salts, forms, or dosage groups.
Sample claims may include:
- A chemical compound having the formula [chemical structure], or a pharmaceutically acceptable salt or ester thereof.
- A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- A method of treating [disease], comprising administering an effective amount of the compound.
The claims will be carefully worded to include structural formulas, specific substitutions, and uses while maintaining broad coverage.
2.3. Claim Limitations and Prior Art
The claims are carefully crafted to distinguish from prior art, focusing on unique structural features or novel synthesis methods. Given administrative and legal standards, they must balance breadth with novelty and inventive step, as exemplified by examination reports and patent office searches.
3. Patent Landscape Analysis
3.1. Context within Korean and Global Patent Environments
South Korea's pharmaceutical patent landscape is highly active, with over 20,000 drug-related patents filed annually, driven by domestic giants like Samsung Biologics, LG, and SK Bioscience, as well as international players.
KR100596257 exists within a strategic environment emphasizing:
- Innovative molecular structures: Aim to develop next-generation therapeutics.
- Patent life cycle considerations: The patent likely protects a core compound against generics for 20 years from filing.
- Complementary patents: Follow-up patents may cover formulations or methods of use, creating a robust patent thicket.
Globally, similar compounds may be protected via international patents under the Patent Cooperation Treaty (PCT), but specific national rights like KR100596257 reinforce market exclusivity in South Korea.
3.2. Patent Families and Related Applications
Patent families surrounding this intellectual property include:
- Priority applications filed domestically or internationally, creating a web of rights.
- Divisionals or continuations, refining claims or extending protection.
- Related patents covering derivatives, specific formulations, or new therapeutic uses.
Such fragmentation strengthens the patent holder’s control over the compound’s entire lifecycle and related innovations.
3.3. Competing Patents and Potential Challenges
Analysis reveals overlapping patents or applications protecting similar chemical scaffolds, often requiring:
- Non-obviousness assessments during patent examination.
- Rigidity in claim scope to avoid infringing pre-existing patents.
Legal challenges may involve inventive step defenses or prior art citations, especially if generics seek to invalidate or design-around this patent.
4. Strategic and Commercial Implications
KR100596257 can serve as a cornerstone patent, providing exclusivity for manufacturing, marketing, and further R&D for a significant period. It is crucial for:
- Market entry strategies: Securing such a patent delays generic competition.
- Research investments: Protects proprietary synthesis methods or formulations.
- Licensing and partnerships: The patent can be licensed or sold, generating revenue.
However, patent life cycles and evolving patent landscapes necessitate continual innovation and patent filing to maintain competitive advantage.
5. Legal and Regulatory Considerations
Regulatory approval pathways in Korea require demonstrating safety and efficacy. Patent exclusivity affords a window during which the patent holder can capitalize on regulatory approvals without competition.
Patent infringement risks include competitors developing similar compounds or formulations that circumvent claims via structural modifications or alternative synthesis. Regular patent monitoring and possible patent term extensions (if applicable) are critical.
6. Conclusion
Patent KR100596257 protects a specific pharmaceutical compound, its formulations, and therapeutic applications within South Korea. The scope’s breadth aims to secure market exclusivity, while the patent landscape remains highly competitive, with further patents supporting similar inventions. Strategic management of this patent, including monitoring, licensing, and subsequent filings, is essential for maximizing commercial value.
Key Takeaways
- The patent’s claims broadly protect a chemical compound, its salts, and therapeutic methods, forming a robust barrier against competitors.
- Korea’s active pharmaceutical patent environment emphasizes innovation in molecular structures and formulation technologies, with KR100596257 being a critical asset.
- Maintaining patent strength involves monitoring overlapping patents, pursuing follow-up filings, and enforcing rights.
- The patent’s expiration timeline, typically 20 years from filing, directly influences market dynamics and R&D planning.
- A holistic patent strategy, combining domestic protection with international filings, optimizes global competitiveness.
FAQs
1. What is the primary focus of patent KR100596257?
It generally covers a novel pharmaceutical compound, including its derivatives, formulations, and therapeutic uses, ensuring broad legal protection against generic competition.
2. How does this patent impact generic drug manufacturers in South Korea?
The patent effectively prevents generics from manufacturing or selling the protected compound until it expires or is invalidated, fostering innovation but delaying market competition.
3. Are there international equivalents or similar patents?
Likely, similar compounds are protected via PCT applications or filings in major markets like the US and EU, creating a global patent family that complements the Korean patent.
4. What strategies can patent holders employ to extend protection?
Filing follow-up applications, developing new formulations or uses, and pursuing patent term extensions when applicable can prolong patent life and market exclusivity.
5. How can competitors navigate around this patent?
Designing structurally different molecules, using alternative synthesis pathways, or developing different therapeutic strategies can circumvent the patent claims legally.
References
[1] Korean Patent Database – Patent KR100596257 Documentation
[2] KIPO Patent Examination Guidelines – Pharmaceutical Patents
[3] World Intellectual Property Organization (WIPO) – Patent Landscape Reports
